| Research & Development (R&D) |
The drug spent almost a decade in clinical trials, exploring dozens of cancer types before gaining FDA approval. The cost of those trials (and the associated risk of failure) is a core part of the price that the company must recoup. |
| Patent & Exclusivity |
Keytruda is protected by patents that cover the antibody itself, its manufacturing process, and its use in specific cancers. Exclusive marketing rights mean no direct competition for a period of time, which lets the company charge a premium. |
| Manufacturing Complexity |
Monoclonal antibodies are built in living cells (often CHO cells) and require highly sterile, temperature‑controlled environments. The raw materials, cell‑culture facilities, and downstream purification steps add to the per‑dose cost. |
| Regulatory & Quality Compliance |
Meeting Good Manufacturing Practice (GMP) standards, extensive quality‑control testing, and ongoing regulatory inspections all add to the overhead that is reflected in the price. |
| Clinical‑Benefit Profile |
Keytruda has shown significant improvements in overall survival and durable responses in several cancers (melanoma, NSCLC, head‑and‑neck, bladder, etc.). Payers consider the drug’s clinical benefit when negotiating price; the bigger the benefit, the higher the willingness to pay. |
| Market Competition & Reference Pricing |
In the U.S., the price is partly benchmarked against other PD‑1/PD‑L1 inhibitors (e.g., nivolumab, durvalumab). In other regions, reimbursement agencies look at international price references and local budgets. The presence of biosimilars (currently none for Keytruda, but they could emerge) will also influence future pricing. |
| Reimbursement & Coverage Policies |
Payers (private insurers, Medicare/Medicaid, national health services) negotiate rebates, copay caps, and risk‑sharing agreements. The size of these rebates can be substantial, so the sticker price on the label is often higher than the net price after discounts. |
| Value‑Based Pricing & Health‑Technology Assessment (HTA) |
In many countries, agencies like NICE (UK), CADTH (Canada), or the Australian PBAC evaluate the cost‑effectiveness of a drug (cost per QALY gained). A higher cost‑effectiveness threshold can justify a higher list price. |
| Supply Chain & Distribution Costs |
From the manufacturer to pharmacies to hospitals, each step adds a margin. Cold‑chain requirements for biologics (strict temperature control) also drive logistics expenses. |
| Patient Population & Utilization |
The broader the approved indications, the larger the potential market. A drug that can treat multiple cancers can command a higher price because it is “selling” more therapeutic “units” to more patients. |
| Policy & Political Factors |
In the U.S., the “two‑year rule” (the period after the first 24 months of market exclusivity during which a manufacturer can raise prices) has been used to justify steep price increases. Political pressure, public scrutiny, and media campaigns can also affect pricing decisions and subsequent negotiations. |